Mounjaro, Eli Lilly's (NYSE:LLY) rival weightloss drug to Wegovy and Ozempic, is to be made available in the UK after receiving the regulatory green light. The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved a four-dose version of Mounjaro KwikPen to treat adults with type 2 diabetes and for weight management in obese and heavily overweight adults who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems. The medicine is ...

Eli Lilly (LLY) closed the latest trading day at $629.68, indicating a -0.19% change from the previous session's end. This change lagged the S&P 500's 0.29% gain on the day. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.43%.The drugmaker's stock has climbed by 10.6% in the past month, exceeding the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. ...

An Eli Lilly & Co. LLY, -0.50% experimental gene therapy has restored the hearing of a child who was born deaf, the pharmaceutical giant said Tuesday. The child, who was 11 years old at the time the therapy was administered, experienced restored hearing within 30 days of treatment, Eli Lilly said in a release. The child participating in the clinical study was the first individual in the U.S. to receive the therapy for a genetic form of hearing loss, the company said. The gene therapy, AK-OTOF, is being deve ...

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF)INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial ...

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be p ...

Eli Lilly (LLY 0.37%) is a highly successful business, and as with any big corporate success story, some critics will offer a counter-narrative of stagnation and decay lurking in the background. However, frequently enough, such bearish overtures are missing key pieces of context, or interpreting important facts incorrectly.In Eli Lilly's case, there are (at least) three misleading tidbits that investors should know about and understand. Let's dive in and analyze why each of these facts are less important th ...

CNBC's Jim Cramer on Monday suggested Tesla could lose its spot in the "Magnificent Seven" megacap stocks list.He said he's waiting to see results from the electric vehicle giant's upcoming earnings report, but said Tesla may have hit a "growth pause," compared to its Big Tech peers that are still on the rise. If Tesla falls out of favor, he said he thinks pharmaceutical giant Eli Lilly is a solid contender to take the company's place.The other members of the Magnificent Seven include Apple, Amazon, Alphabe ...

After years of a slowdown in performance and revenue, Eli Lilly (NYSE: LLY) is starting to turn the page. With its innovations in the pharmaceutical sector, most notably in diabetes treatment, its medications performed well, raking in a huge chunk of revenue and propelling this pharmaceutical giant to the 10th largest company by market cap.Eli Lilly’s latest pharmaceutical product for diabetes and obesity, Mounjaro (marketed as Zepbound for weight management), is anticipated to potentially emerge as the hig ...

The healthcare sector is home to many excellent, innovative corporations that have made many investors richer. However, no healthcare company has reached a market capitalization of $1 trillion. Perhaps that's not so surprising. After all, very few companies are part of this elite club.But it's only a matter of time until one healthcare stock finally hits that goal, so which one will do it first? My money is on Eli Lilly (LLY 0.84%). Let's find out why.Meet the candidatesLet's start with a list of some healt ...

Shares of Eli Lilly (LLY 0.84%) can't seem to stop rallying. For investors thinking about whether to buy the stock, it can be both exciting and discouraging to see it rise. While it's encouraging to see the stock going in the right direction, it's also potentially discouraging to not see it dip in value, where there might be a potential buying opportunity.Given the stock's impressive gains -- it's up around 80% in just 12 months -- is it too late to invest in Eli Lilly right now? Should investors continue w ...